FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for RYDAPT (midostaurin) from Novartis, updating the regulatory status of the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with Flt3 Mutation
• Aggressive Systemic Mastocytosis
• Systemic Mastocytosis
• Systemic Mastocytosis with An Associated Hematologic Neoplasm

Drugs mentioned

• Rydapt (midostaurin)

Snippet

SUPPL AP for RYDAPT (RYDAPT)